ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,222.68
0.16%
Dow Jones
39,512.84
0.32%
US Dollar vs MXN
16.7804
0.00%
Brent Oil
82.585
0.00%
Bitcoin
61,072.92
0.46%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Novelion Therapeutics Inc (NVLN)

  7. Novelion Therapeutics Inc (NVLN) Noticias

NVLN

Novelion Therapeutics (NVLN)

Novelion Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:NVLN
FechaHoraFuenteTítuloSímboloCompañía
30/03/202015:30Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)NASDAQ:NVLNNovelion Therapeutics Inc
13/02/202015:52Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:NVLNNovelion Therapeutics Inc
21/01/202016:24Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NVLNNovelion Therapeutics Inc
15/01/202016:26Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:NVLNNovelion Therapeutics Inc
17/12/201912:38Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...NASDAQ:NVLNNovelion Therapeutics Inc
12/12/201915:25Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NVLNNovelion Therapeutics Inc
15/11/201915:33Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)NASDAQ:NVLNNovelion Therapeutics Inc
08/10/201907:10GlobeNewswire Inc.Novelion Therapeutics Announces Nasdaq DelistingNASDAQ:NVLNNovelion Therapeutics Inc
08/10/201907:01Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:NVLNNovelion Therapeutics Inc
03/10/201917:21GlobeNewswire Inc.Novelion Therapeutics Announces Filing of Definitive Proxy Statement in Connection with Proposed Liquidation and Other Matter...NASDAQ:NVLNNovelion Therapeutics Inc
03/10/201916:18Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:NVLNNovelion Therapeutics Inc
27/09/201916:01Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:NVLNNovelion Therapeutics Inc
25/09/201907:25GlobeNewswire Inc.Novelion Therapeutics Announces Completion of Aegerion Transaction and Departure of Certain Directors and OfficersNASDAQ:NVLNNovelion Therapeutics Inc
20/09/201916:23Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:NVLNNovelion Therapeutics Inc
11/09/201916:50GlobeNewswire Inc.Novelion Therapeutics Announces US Court Confirmation of Aegerion Bankruptcy Case, Update on Nasdaq Delisting and Date of Ann...NASDAQ:NVLNNovelion Therapeutics Inc
30/08/201907:02GlobeNewswire Inc.Novelion Therapeutics Provides Update Regarding Delisting from Nasdaq and Aegerion Bankruptcy CaseNASDAQ:NVLNNovelion Therapeutics Inc
23/08/201916:10Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:NVLNNovelion Therapeutics Inc
21/08/201916:09GlobeNewswire Inc.Novelion Therapeutics Announces Issuance of General Cease Trade Order in Canada and Notice of Delisting from NasdaqNASDAQ:NVLNNovelion Therapeutics Inc
12/08/201915:34GlobeNewswire Inc.Novelion Therapeutics Announces Anticipated Late Filing of Quarterly Report on Form 10-Q for the Quarter Ended June 30, 2019NASDAQ:NVLNNovelion Therapeutics Inc
16/07/201917:43GlobeNewswire Inc.Novelion Therapeutics Announces Dismissal of Whitefort Capital PetitionNASDAQ:NVLNNovelion Therapeutics Inc
05/07/201907:30GlobeNewswire Inc.Novelion Therapeutics Receives Delisting NotificationsNASDAQ:NVLNNovelion Therapeutics Inc
24/06/201907:30GlobeNewswire Inc.Novelion Therapeutics Responds to Whitefort Capital PetitionNASDAQ:NVLNNovelion Therapeutics Inc
20/05/201921:53GlobeNewswire Inc.Novelion Therapeutics Announces Subsidiary Aegerion Pharmaceuticals to Recapitalize Through Court Supervised Process In Which...NASDAQ:NVLNNovelion Therapeutics Inc
07/05/201915:18Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NVLNNovelion Therapeutics Inc
07/05/201915:01GlobeNewswire Inc.Novelion Therapeutics Reports First Quarter 2019 Financial ResultsNASDAQ:NVLNNovelion Therapeutics Inc
26/04/201908:01Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:NVLNNovelion Therapeutics Inc
31/03/201901:00GlobeNewswire Inc.Novelion Therapeutics Observes World Lipodystrophy DayNASDAQ:NVLNNovelion Therapeutics Inc
29/03/201913:29Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:NVLNNovelion Therapeutics Inc
15/03/201915:06Edgar (US Regulatory)Annual Report (10-k)NASDAQ:NVLNNovelion Therapeutics Inc
14/03/201916:12GlobeNewswire Inc.Novelion Therapeutics Reports Fourth Quarter and Full Year 2018 Financial ResultsNASDAQ:NVLNNovelion Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NVLN

Su Consulta Reciente

USOTC
BNPQY
BNP Paribas (QX)
NYSE
BAC
Bank of America
AMEX
XLF
Financial Select Sector
SPI
SP500
S&P 500
NYSE
JPM
JP Morgan Chase
AMEX
XLV
Health Care Select Sector
FX
EURUSD
Euro vs US Dollar
FX
EURMXN
Euro vs MXN
NYSE
CVX
Chevron
AMEX
SPY
SPDR S&P 500
USI
USTECH100
US Tech 100
USOTC
RHHBY
Roche (QX)
NYSE
VZ
Verizon Communications
NASDAQ
TSLA
Tesla
FX
USDMXN
US Dollar vs MXN
USOTC
BASFY
BASF (QX)
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados